Track topics on Twitter Track topics that are important to you
Express Scripts will begin covering Vyzulta under an agreement with Bausch + Lomb, according to a press release.
Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), indicated for reducing IOP in patients with open-angle glaucoma or ocular hypertension, will be covered under an access position on the commercial Express Scripts National Preferred and Basic formularies, the release said.
“We are proud of this achievement as it signifies the health care community’s recognition of the benefit Vyzulta may offer glaucoma patients,” Tracy Valorie, Bausch + Lomb’s senior
Original Article: Insurance coverage of Vyzulta expands with Express ScriptsNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...